Skip to Content
Søk Menu

AML patients with FLT3-ITD and wild-type NPM1 has a significant improvement of LFS, OS and GRFS

Ali Bazarbachi, MD, and PhD at the American University of Beirut in Lebanon, presents in this MEDtalk a report from the EBMT Acute Leukemia Working Party, showing improved post-transplant outcomes for AML patients with intermediate karyotype FLT3-ITD and wild type NPM1.
Ali Bazarbachi

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Relatert innhold

Drug Sensitivity Screening to Guide Clinical Decisions for Hematologic Cancers

/ Sigrid S. Skånland
AMLCLL
Jad Othman

MRD Status in NPM1 Mutated AML Should Be a Part of the Selection of Patients for Transplant in First Remission

/ Jad Othman
AMLASH23 Play the Video 03:32

ASH 2023: Oral Decitabine-Cedazuridine Tablet Shows Promise for AML Treatment in Phase III Study

/ BestPractice Nordic
AMLASH23
Sergio Giralt

In the Era of Personalized Treatment and Targeted Therapies

/ Sergio Giralt
AMLASH23 Play the Video 2:46

Promising Results from EHA23: Gilteritinib as Posttransplant Maintenance Therapy for FLT3-ITD AML Patients

/ BestPractice Nordic
AMLEHA23

FLT3 Inhibitor Gilteritinib Shows Potential in Post-Transplant Maintenance for AML

/ Mark Levis
AMLEHA23 Play the Video 05:06

EHA23 – Novel CAR Therapy for AML Shows Favorable Pre-Clinical Outcomes

/ BestPractice Nordic
AMLCAR-TEHA23
Christine Ryan

Updated results on AVO therapeutic triplet regimen in untreated patients with CLL

/ Christine Ryan
ASH22CLL Play the Video 8:04
Ryan Jacobs

CLL – The impact of using ibrutinib as front-line treatment

/ Ryan Jacobs
ASH22CLL Play the Video 8:06
Back to top